212 related articles for article (PubMed ID: 16226489)
21. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.
Lefebvre AM; Peinado-Onsurbe J; Leitersdorf I; Briggs MR; Paterniti JR; Fruchart JC; Fievet C; Auwerx J; Staels B
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1756-64. PubMed ID: 9327774
[TBL] [Abstract][Full Text] [Related]
22. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.
Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
J Lipid Res; 2001 Feb; 42(2):241-8. PubMed ID: 11181754
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia.
Allayee H; Castellani LW; Cantor RM; de Bruin TW; Lusis AJ
Circ Res; 2003 Jun; 92(11):1262-7. PubMed ID: 12738753
[TBL] [Abstract][Full Text] [Related]
24. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
25. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility.
Martín-Campos JM; Escolà-Gil JC; Ribas V; Blanco-Vaca F
Curr Opin Lipidol; 2004 Jun; 15(3):247-53. PubMed ID: 15166779
[TBL] [Abstract][Full Text] [Related]
27. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
[TBL] [Abstract][Full Text] [Related]
28. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice.
Chroni A; Kan HY; Shkodrani A; Liu T; Zannis VI
Biochemistry; 2005 Mar; 44(10):4108-17. PubMed ID: 15751988
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression.
Singh JP; Kauffman R; Bensch W; Wang G; McClelland P; Bean J; Montrose C; Mantlo N; Wagle A
Mol Pharmacol; 2005 Sep; 68(3):763-8. PubMed ID: 15933217
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Hiukka A; Leinonen E; Jauhiainen M; Sundvall J; Ehnholm C; Keech AC; Taskinen MR
Diabetologia; 2007 Oct; 50(10):2067-75. PubMed ID: 17653691
[TBL] [Abstract][Full Text] [Related]
31. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
Vu-Dac N; Schoonjans K; Kosykh V; Dallongeville J; Fruchart JC; Staels B; Auwerx J
J Clin Invest; 1995 Aug; 96(2):741-50. PubMed ID: 7635967
[TBL] [Abstract][Full Text] [Related]
32. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice.
Tailleux A; Bouly M; Luc G; Castro G; Caillaud JM; Hennuyer N; Poulain P; Fruchart JC; Duverger N; Fiévet C
Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2453-8. PubMed ID: 11073852
[TBL] [Abstract][Full Text] [Related]
33. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
Liu C; Guo Q; Lu M; Li Y
Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
[TBL] [Abstract][Full Text] [Related]
34. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
Andersson Y; Majd Z; Lefebvre AM; Martin G; Sechkin AV; Kosykh V; Fruchart JC; Najib J; Staels B
Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):115-21. PubMed ID: 9888873
[TBL] [Abstract][Full Text] [Related]
35. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein.
Blanco-Vaca F; Escolà-Gil JC; Martín-Campos JM; Julve J
J Lipid Res; 2001 Nov; 42(11):1727-39. PubMed ID: 11714842
[TBL] [Abstract][Full Text] [Related]
36. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.
Bisgaier CL; Essenburg AD; Barnett BC; Auerbach BJ; Haubenwallner S; Leff T; White AD; Creger P; Pape ME; Rea TJ; Newton RS
J Lipid Res; 1998 Jan; 39(1):17-30. PubMed ID: 9469582
[TBL] [Abstract][Full Text] [Related]
37. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice.
Weng W; Brandenburg NA; Zhong S; Halkias J; Wu L; Jiang XC; Tall A; Breslow JL
J Lipid Res; 1999 Jun; 40(6):1064-70. PubMed ID: 10357838
[TBL] [Abstract][Full Text] [Related]
38. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice.
Weinstock PH; Bisgaier CL; Hayek T; Aalto-Setala K; Sehayek E; Wu L; Sheiffele P; Merkel M; Essenburg AD; Breslow JL
J Lipid Res; 1997 Sep; 38(9):1782-94. PubMed ID: 9323588
[TBL] [Abstract][Full Text] [Related]
39. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
[TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
Huang Y; Schwendner SW; Rall SC; Sanan DA; Mahley RW
J Biol Chem; 1997 Sep; 272(36):22685-94. PubMed ID: 9312550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
